Humana Is Set Up For Long-Term Success
Humana Inc. is having short-term cost challenges and facing constrained rate increases. However, Humana's Medicare Advantage expected to benefit from demographic tailwinds and CenterWell integrated care for growth and cost mitigation. I rate Humana a buy at a price target of $396.
The Schall Law Firm is urging investors who have suffered losses in Humana Inc. to get in touch
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.
Humana (HUM) Partners With UAB to Boost Care for MA Members
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Why Is Humana (HUM) Up 13.1% Since Last Earnings Report?
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
